Background: Cannabis is one of the most commonly used substances in patients with a psychotic disorder and is associated with a higher risk of psychotic relapses. Identifying reasons for cannabis use and subjective effects in patients with psychotic disorders can provide insight into the functions of cannabis use, and this may lead to targeted interventions.
Methods: A literature search of the PubMed and PsycINFO databases for articles published from 1985 till 2008 was carried out to review studies that examined self-reported reasons for cannabis use and self-reported effects of cannabis use in patients with psychotic disorders.
Results: Only a few studies were found that specifically assessed reasons for and effects of cannabis use. Despite the heterogeneity in the study samples and methodology, patients commonly reported that their reasons for cannabis use were enhancement of positive affect, relief of dysphoria and social enhancement. Fewer patients reported reasons related to relief of psychotic symptoms or relief of side effects of medication. Frequently reported positive effects of cannabis were positive changes in affect and relaxation. A large proportion of patients reported that cannabis negatively affected positive symptoms.
Conclusions: Patients suffering from psychotic disorder report using cannabis mainly for affect regulation and socialization, despite the awareness that cannabis has a negative effect on positive symptoms. In spite of the heterogeneity of the studies, the results turned out to be broadly comparable and support the external validity of this review to a broad range of cannabis-using patients with psychotic disorder.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000236906 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose Of Review: This review examines the literature associating cannabis with schizophrenia, glutamate dysregulation in schizophrenia, and cannabis involvement in glutamate pathways. Cannabis use is widespread among adolescents world-wide and is sold legally in many countries for recreational use in a variety of forms. Most people use it without lasting effects, but a portion of individuals have negative reactions that manifest in acute psychotic symptoms, and in some, symptoms continue even after the use of cannabis has ceased.
View Article and Find Full Text PDFPsychosocial Interventions in the Rehabilitation and the Management of Psychosis and Schizophrenia: A Systematic Review on Digitally-Delivered Interventions.
Actas Esp Psiquiatr
March 2025
Unit of Clinical Psychiatry, Department of Clinical Neurosciences/DIMSC, Polytechnic University of Marche, 60126 Ancona, Italy.
Background: Schizophrenia and psychotic disorders are disabling, complex and severe psychiatric conditions, which may pose a significant therapeutic challenge. Integrating current psychopharmacological treatment with psychosocial interventions demonstrated a higher efficacy in terms of prognosis. However, most schizophrenia or psychotic patients may have restricted or no access to evidence-based psychosocial interventions, mainly due to poor dissemination of specialized interventions or stigma.
View Article and Find Full Text PDFCerebellar-Cortical Connectivity and Prediction of Antipsychotic Treatment Response in First-Episode Psychosis.
Schizophr Bull
March 2025
Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, NY 11030, United States.
Background: The cerebellum has traditionally been associated with motor functions, but recent evidence highlights its critical role in cognitive and emotional regulation, contributing to the neuropathology of schizophrenia. Our previous data-driven research demonstrated that cerebellar-cortical functional connectivity can predict antipsychotic treatment outcomes in first-episode psychosis (FEP). The present study aimed to investigate specific cerebellar functional systems involved in treatment prediction.
View Article and Find Full Text PDFOptimal Treatment of Magnetic Seizure Therapy (MST) in Patients with Clozapine-Resistant Schizophrenia (CRS).
Neuropsychiatr Dis Treat
March 2025
Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Objective: The study aims to compare the clinical efficacy and cognitive side effect of magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) on clozapine resistant schizophrenia (CRS).
Methods: Sixteen patients with CRS were enrolled in this randomized, parallel-group, controlled clinical trial. Patients were randomly allocated to receive 10 sessions of add-on MST or MECT over 4 weeks (1:1 ratio) and continued clozapine therapy during the study.
Comparative risk of QTc prolongation induced by second-generation antipsychotics in the real world: retrospective cohort study based on a hospital information system.
BJPsych Open
March 2025
Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Background: Second-generation antipsychotics (SGAs) can cause corrected QT interval (QTc) prolongation as a side-effect. This may limit their clinical use and pose safety concerns for patients.
Aims: To analyse the risk of QTc prolongation associated with eight second-generation antipsychotics and observe the timing characteristics of QTc prolongation events and subsequent changes in medication strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!